Retrospective Analysis of the Effects of Enzymotec's Vayarin(R) Showed Significant Improvement of Emotional Status and Sleep Quality in ADHD Patients With Sleep Disturbances

MIGDAL HA'EMEQ, Israel, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enyzmotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that a poster entitled "ANALYZING THE EFFECT OF VAYARIN® ON EMOTIONAL REGULATION AND SLEEP QUALITY IN ADHD PATIENTS SUFFERING FROM SLEEP DISTURBANCES" was presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd annual meeting by Dr. Arnold Mech, Medical Director and Head of The Mech Center Outpatient and Research, Sleep Centers of Texas. The poster presentation outlined the results of a retrospective analysis that evaluated the effect of Vayarin® on emotional regulation and sleep quality in ADHD patients suffering from sleep disturbances.

Vayarin®, a unique prescription-based medical food that addresses lipid imbalances associated with ADHD, has been demonstrated to significantly reduce ADHD symptoms, especially in children with emotional dysregulation. Additionally, Vayarin® has been clinically shown to be safe and well-tolerated in children.

In the present analysis, the effect of Vayarin® was retrospectively evaluated in patients with ADHD, who also suffered from sleep disturbances, identified through patient electronic health records (EHR). A self-assessed emotional dysregulation inventory (MEDI-Mech), as well as Polysomnography (PSG) and the Fatigue Assessment Scale (FAS), were used to assess the effect of Vayarin® on emotional dysregulation and sleep quality.

Results showed that Vayarin® significantly improved emotional status and quality of sleep, as demonstrated by a significant increase in Rapid Eye Movement (REM). In addition, the majority of participants reported an improvement in fatigue symptoms.

Rob Crim, VAYA Pharma's Chief Executive Officer, commented, "We are pleased by the results of this retrospective study on Vayarin. We look forward to continuing to be able to demonstrate the positive effects in ADHD patients."

About VAYA Pharma

VAYA Pharma is a specialty pharmaceutical division of Enzymotec Ltd. dedicated to the discovery, development, manufacture and marketing of innovative lipid-based compositions familiar to the human body for addressing disorders that are impacted by lipid imbalances.

VAYA Pharma's medical food portfolio addresses three therapeutic segments: ADHD (Vayarin®), Early Memory Impairment (Vayacog®) and Hypertriglyceridemia (Vayarol®). VAYA Pharma products are available in the U.S. only by prescription under the supervision of a physician. VAYA Pharma USA is headquartered in Baltimore, Maryland. For more information, visit and

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures, and markets innovative bio-active lipid based nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies intended to improve people's health. For more information, visit

CONTACT: The Ruth Group Tram Bui/Lee Roth #646-536-7035/7012

Source:Enzymotec Ltd.